Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer. Another allogeneic, shRNA-based CAR-T candidate, CYAD-211, is in Phase 1 for individuals suffering from relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T therapy, is being evaluated in Phase 1 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, Celyad is developing CYAD-203. This is a non-gene edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 (IL-18) alongside natural killer group 2D ligands (NKG2D), targeting solid tumors. Celyad has also forged strategic alliances. It holds a licensing agreement with Novartis International AG concerning US patents for allogeneic CAR-T cell technology. Furthermore, the company has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to establish a second non-gene-edited allogeneic platform. Founded in 2004, the company was initially named Celyad SA, but rebranded to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.